6
Tseluiko A, Semiglazov V, Kudaibergenova A, Urezkova M, Artemieva A, Krivorotko P. The role of tumor-infiltrating lymphocytes, prognostic and predictive signification in breast cancer. In: 17th St. Gallen International Breast Cancer Conference/The Breast 56S1; 2021: P118, S65.
9
Emens L, Nanda R. Breast cancer immunotherapy. In: Butterfield L, Kaufman H, Marincola F, Sectrion Ⅳ, Ascieto P, editors. Cancer immunotherapy. Principal and practice. 2017, 702-16[chapter 46].
21
Urezkova M, Kudaybergenova A, Semiglazova T, Semiglazov V, Tseluiko A, Artemyeva A, et al. TILs in triple –positive breast cancer. In: 17th St Gallen breast cancer conference, 2021, Poster Abstract/The Breast 56S1(2021), P027, S17-90.
39
I-SPY2 Trial Consortium: Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, et al. Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncol. 2020, 6: 1355-62.
41
Liu MC, Robinson PA, Yau C, Wallace AM, Chien A, Stringer-Reasor E, et al. Evaluation of a pembrolizumab-8 cycle neoadjuvant regimen without AC for high-risk early-stage HER2-negative breast cancer: results from the I-SPY 2 TRIAL. Presented at the 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. Abstract P3-09-02.
69
Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. In: Presented at the 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019, San Antonio, Texas. Abstract GS3-04. 37.